In a recent episode of the Denatured podcast, Jennifer C. Smith-Parker spoke with Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. The discussion focused on the evolving landscape of obesity treatments beyond current GLP-1 therapies.
The conversation addressed how new therapies are aiming to tackle some limitations associated with GLP-1 drugs, such as muscle loss and challenges related to patient adherence. The guests highlighted efforts to improve outcomes by focusing on muscle preservation, exploring oral administration options, and considering combination treatment approaches.
Jane Hughes and Jon Rees shared their perspectives on how these next-generation treatments could address gaps left by existing medications. The podcast emphasized that the views expressed by the guests were their own and did not represent those of their respective organizations.
